Competing interests
BG reports research funding and/or consulting (all paid to his institution) for Abbvie, Accutar Biotechnology, Arcus Biosciences, Arvinas, AstraZeneca, AVEO Oncology, CRISPIR Therapeutics, Eikon Therapeutics, Exelixis, Roche/Genetech, Flare Therapeutics, Harbor BioMed, IDEAYA Biosciences, Janssen, Janux Therapeutics, Jubilant Therapeutics, Kineta, Kinnate BioPharma, Loxo, Mink Therapeutics, Nuvation Bio, Profound Bio, Takeda Therapeutics, Teon Therapeutics, Tmunity Therapeutics, Xencor, Zenshine, Adaptimune, Adicet Therapeutics, AIQ Global, Amgen, Arcus Biosciences, Bayer, Bicycle Therapeutics, Easai, EMD Serono, Merck, Novartis, Pfizer, Rondo Therapeutics, Sanofi-Aventis, Seagen, Xencor. FAG reports payments from Hologic/BioTheranostics, for JS from 2022 to present JS has been Editor-in-Chief of Oncogene (no role in the review process here) and has sat on SABs/advisory boards for Lilly, Agenus, Celltrion, Enhanced, Glyphic, Greenmantle, vTv Therapeutics, APIM, Onconox, IO Labs, Clinical Ink, Zephyr AI, Benevolent AI, Biozen, Pear Bio, Sable Bio and Linkgevity. He has consulted with Lansdowne partners and Vitruvian. Since 2024 he has been a board member for Graviton Bioscience BV, Etira Therapeutics and Portage, and previously chaired the board of BB Biotech Healthcare Trust PLC. All other authors report employment, shares and salaries at MiNK Therapeutics or Agenus Inc.
